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oRIGINAL ARTICLE
Introduction: We evaluated the ability of histopathologic response 
criteria to predict overall survival (oS) and disease-free survival 
(DFS) in patients with surgically resected non-small cell lung cancer 
(NSCLC) treated with or without neoadjuvant chemotherapy.
Methods: Tissue specimens from 358 patients with NSCLC were 
evaluated by pathologists blinded to the patient treatment and out-
come. The surgical specimens were reviewed for various histopatho-
logic features in the tumor including percentage of residual viable 
tumor cells, necrosis, and fibrosis. The relationship between the his-
topathologic findings and oS was assessed.
Results: The percentage of residual viable tumor cells and surgical 
pathologic stage were associated with oS and DFS in 192 patients with 
NSCLC receiving neoadjuvant chemotherapy in multivariate analysis 
(p = 0.005 and p = 0.01, respectively). There was no association of 
oS or DFS with percentage of viable tumor cells in 166 patients with 
NSCLC who did not receive neoadjuvant chemotherapy (p = 0.31 and 
p = 0.45, respectively). Long-term oS and DFS were significantly 
prolonged in patients who had 10% viable tumor compared with 
patients with >10% viable tumor cells (5 years oS, 85% versus 40%, 
p < 0.0001 and 5 years DFS, 78% versus 35%, p < 0.001).
Conclusion: The percentages of residual viable tumor cells pre-
dict oS and DFS in patients with resected NSCLC after neoadju-
vant chemotherapy even when controlled for pathologic stage. 
Histopathologic assessment of resected specimens after neoadjuvant 
chemotherapy could potentially have a role in addition to pathologic 
stage in assessing prognosis, chemotherapy response, and the need 
for additional adjuvant therapies.
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Surgical resection is the treatment of choice in patients with localized non-small cell lung cancer (NSCLC).1 
Neoadjuvant chemotherapy followed by resection has been 
used in patients with locally advanced NSCLC to address 
the high rate of local and systemic failure.2–5 Histopathologic 
features in the resected specimen of patients receiving neoad-
juvant chemotherapy or chemoradiation have been reported 
in a small number of studies to be useful in the prediction 
of survival and assessment of tumor response after neoadju-
vant treatment.6–17 The purpose of this study was to assess in a 
larger cohort of patients the ability of histopathologic criteria 
to predict survival and chemotherapy response in patients with 
NSCLC treated with neoadjuvant chemotherapy even when 
controlled for surgical pathologic stage.
PATIENTS AND METHODS
Patients and Tissue Samples
We examined 192 patients with NSCLC treated with 
neoadjuvant chemotherapy followed by complete surgical 
resection from 2001 to 2006. We also examined a control 
group of 166 patients with NSCLC from the same time period 
who did not receive neoadjuvant chemotherapy. Histologic 
slides from the files of the Department of Pathology, M. D. 
Anderson Cancer Center18 and all cases were reviewed. The 
study was approved by the University of Texas M. D. Anderson 
Institutional Review Board.
Histopathologic Evaluation
Hematoxylin and eosin-stained slides of sections of the 
gross residual tumor were assessed in a total of 358 patients by 
pathologists blinded to the patient treatment and outcome. In 
this study, at least 1 section per cm of tumor greatest diameter 
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was obtained. The number of slides examined for each case 
ranged from 5 to 30. Figure 1 shows the schematic diagram 
for histopathologic evaluation of NSCLC. The percentage 
of residual tumor was estimated by comparing the estimated 
cross-sectional area of the viable tumor foci with estimated 
cross-sectional areas of necrosis, fibrosis, and inflammation 
on each slide. Histologic parameters were analyzed including 
necrosis, fibrosis, foamy macrophages, giant cell reaction, cho-
lesterol cleft granuloma, and inflammation. The results for all 
slides were averaged together to determine the mean values for 
each patient. All histopathologic changes were then compared 
with patients who had not received neoadjuvant chemotherapy.
Statistical Analysis
overall survival (oS) was defined as the time from date 
of the surgery until death from any cause. Disease-free sur-
vival (DFS) was defined as the time from surgery until time of 
the tumor recurrence or date of last follow-up. Survival prob-
ability as a function of time was computed by the Kaplan-
Meier estimator. The log-rank test was used to compare patient 
survival times between groups. Univariable Cox proportional 
hazards regression model was used to examine the associa-
tion between histopathologic features and various clinical 
factors with oS and DFS. The variables found significant on 
univariate analysis (p value < 0.25) were evaluated by multi-
variable analysis using the Cox proportional hazards model 
after backward stepwise Wald elimination. A p value of less 
than 0.05 on multivariate analysis was taken to be significant. 
The statistical analyses were performed using SPSS Software 
(version 15; SPSS, Inc., Chicago, IL).
RESULTS
Patient Demographics and Treatment 
Characteristics
Table 1 presents the patient demographics of the patients 
with NSCLC treated with and without neoadjuvant  chemotherapy. 
Patients treated with neoadjuvant chemotherapy tended to have a 
higher clinical and pathologic stage. There was some evidence of 
clinical downstaging in the resected specimens of the neoadju-
vant-treated patients (clinical stage IIIA/B 41%, pathologic stage 
IIIA/B 30%, p < 0.05), which was not seen in patients treated 
with surgery alone. Neoadjuvant-treated patients also tended to 
have more patients classified as “other” on histology (NSCLC-
not otherwise specified, adenosquamous, and neuroendocrine 
carcinoma). No difference was noted between groups in the type 
or extent of surgery. The majority of patients with NSCLC 
treated with neoadjuvant chemotherapy received a platinum and 
FIGURE 1. Schematic diagram of histologic evaluation of lung cancer tissue resected from patients treated with neoadjuvant 
chemotherapy.
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taxane-based regimen (171 patients, 89%, Table 1). The median 
number of treatment cycles was three cycles (range: 2–7 cycles).
Histopathologic Features in Patients Treated 
with and without Neoadjuvant Chemotherapy
Histopathologic patterns observed with treatment-
induced tumor regression included necrosis, fibrosis, foamy 
macrophages, cholesterol cleft granuloma, giant cell reac-
tion, and inflammation. Figure 2 shows typical examples 
of the histopathologic features of tumors associated with 
extensive (A and C) or no (B and D) response to neoadjuvant 
chemotherapy.
We compared the percentage of viable tumor cells in 
patients treated with or without neoadjuvant chemotherapy. 
In patients treated with neoadjuvant chemotherapy, 36 (19%) 
of 192 patients had 10% viable tumor cells (Table 2). All 
patients who underwent surgery alone had >10% viable tumor 
cells (Table 2). The percentage of viable tumor cells was a 
significant predictor of the survival only in the patients with 
NSCLC who received neoadjuvant chemotherapy (Table 2, 
p < 0.003). There was no relationship with survival in patients 
with NSCLC who did not receive neoadjuvant chemotherapy 
(Table 2). Compared with patients with 10% viable tumor 
cells, the hazard ratio for neoadjuvant-treated patients with 
NSCLC with >70% viable tumor cells was 4.78 with a 95% 
confidence interval of 2.06–11.11.
Histopathologic Criteria of Chemotherapy 
Response and Pathologic Stage are Associated 
with Long-Term Survival
We analyzed the relationship between pathologic stage 
and survival in patients with neoadjuvant-treated NSCLC 
and found that even after chemotherapy the pathologic stage 
was a significant predictor of long-term survival (Figure 3). 
The percentage of viable tumor cells in the resected specimens 
was also a significant predictor of long-term survival after 
neoadjuvant chemotherapy when assessed in a categorical 
(Figure 3) or continuous fashion (Table 3). Multivariable anal-
ysis (Table 3) suggests that the significant predictors of oS 
and DFS after neoadjuvant chemotherapy include pathologic 
stage and percentage of viable tumor cells. In multivariable 
analysis, for every 1% increase in viable tumor, hazard ratio 
increased by 0.01.
DISCUSSION
Although the survival benefits of neoadjuvant chemo-
therapy remain controversial,2–7 it has been observed that 
pathologic response after neoadjuvant therapy in patients with 
resected stage IIIA NSCLC is associated with improved oS.8 
In a multicenter, phase II trial evaluating pN2 patients treated 
with three cycles of neoadjuvant docetaxel-cisplatin, Betticher 
et al.8 noted that the 60% of patients who downstaged from 
pN2 at mediastinoscopy to pN0-N1 at surgery had improved 
3 years oS (60% versus 10%, p < 0.0001). Several authors 
have also noted that histopathologic response criteria may be 
a prognostic factor in clinical N2 (cN2) patients treated with 
neoadjuvant chemotherapy or chemoradiotherapy.9,10 Because 
of these preliminary observations, we wanted to see whether 
reproducible histopathologic response criteria could be devel-
oped that would predict long-term survival in a larger cohort 
of patients with stages I to III NSCLC treated with neoadju-
vant chemotherapy even when controlled for pathologic stage. 
We also wanted to see whether these criteria might provide a 
surrogate end point for long-term survival and chemotherapy 
response in biomarker-driven translational clinical trials.





Surgery (N = 192)
Surgery 
Alone  
(N = 166) p
Age mean (range) 63 (40–85) 66 (40–90) 0.29
Gender, n (%) 0.31
 Male 111 (58) 79 (48)
 Female 81 (42) 87 (52)
Histology, n (%) <0.0001
 Adenocarcinoma 89 (46) 107 (65)
 Squamous cell  
 carcinoma
58 (30) 55 (33)
 others 45 (24) 4 (2)
Tumor size (cm), n (%) 0.38
 0.0–2.0 47 (25) 24 (15)
 2.1–3.0 49 (25) 46 (28)
 3.1–4.0 32 (17) 39 (23)
 4.1–5.0 21 (11) 28 (17)
 >5.1 43 (22) 29 (17)
Clinical stage, n (%) <0.0001
 IA/IB 60 (31) 118 (71)
 IIA/IIB 44 (23) 30 (18)
 IIIA/IIIB 79 (41) 14 (9)
 IV 9 (5) 4 (2)
Pathologic stage, n (%) <0.0001
 0/IA/IB 78 (40) 98 (59)
 IIA/IIB 49 (26) 45 (27)
 IIIA/IIIB 57 (30) 21 (13)
 IV 8 (4) 2 (1)
Type of resection n (%) 0.69
 Wedge or  
 segmentectomy
5 (2) 7 (4)
 Bilobectomy or  
 lobectomy
174 (91) 148 (89)
 Pneumonectomy 13 (7) 11 (7)
Neoadjuvant chemotherapy, n (%)
 T + C 171 (89)
 Carboplatin 134 (70)
 Cisplatin 58 (30)
 Taxol 98 (51)
 Taxotere 75 (39)
 Gemcitabine 17 (9)
 Etoposide 3 (1)
Treatment cycle mean (range) 3 (2–7)
others of chemotherapy group (39 patients with NSCLC-NoS, 5 with adenosquamous 
carcinoma, and 1 with neuroendocrine carcinoma) and surgery alone group (4 patients 
with NSCLC-not otherwise specified).
T, taxol or taxotere; C, carboplatin or cisplatin; AJCC7, American Joint Committee 
on Cancer 7.
828 Copyright © 2012 by the International Association for the Study of Lung Cancer
Pataer et al. Journal of Thoracic Oncology  •  Volume  7, Number 5, May 2012
FIGURE 2. Pathologic response to neoadjuvant chemotherapy for lung cancer. Representative examples of the histopathol-
ogy of tumors associated with extensive response to treatment (A, C) or no response to treatment (B, D). Arrows indicate viable 
tumor cells (C, D). Original magnification: 340 (pictures) and 3200 (insets).
TABLE 2. Association of Survival with Percentage of Viable Tumor Cells in Patients with NSCLC with or without  
Neoadjuvant Chemotherapy
Percentage of Viable 
Tumor Cells
Neoadjuvant Treatment (N = 192) Surgery Alone (N = 166)
No. of 
Patients (%) HR (95% CI) p
No. of 
Patients (%) HR (95% CI) p
0–10% 36 (19) 1.00 0.003 0 (0) 0.51
11–30% 19 (10) 2.51 (0.91–6.96) 6 (4) 1.00
31–50% 35 (18) 3.39 (1.40–8.22) 27 (16) 1.02 (0.31–3.33)
51–70% 56 (29) 4.57 (1.98–10.52) 64 (38) 0.62 (0.19–1.96)
71–100% 46 (24) 4.78 (2.06–11.11) 69 (42) 0.76 (0.25–2.41)
HR, hazard ratio; CI, confidence interval.
Neoadjuvant chemotherapy is a therapeutic option that 
is used in patients with locally advanced resectable NSCLC. 
The response to neoadjuvant chemotherapy in these patients 
is typically assessed by radiologic measurements of tumor 
size before and after therapy. Unfortunately, this change in 
tumor size is not always reliable in the prediction of long-term 
survival because of the difficulty in differentiating fibrosis 
from viable tumor radiographically. Attempts to improve the 
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prediction of chemotherapy response with positron emission 
tomography/computed tomography findings have also been 
confounded by false-positive F-fluorodeoxyglucose avidity 
due to macrophage infiltration.11 Several small studies have 
suggested that the degree of tumor regression after neoad-
juvant therapy as determined by histopathologic findings in 
the resected tumor may be a more objective criterion of che-
motherapy response (Table 4).12–15 our data on 192 patients 
with NSCLC treated with neoadjuvant chemotherapy suggest 
that the percentage of viable tumor cells does indeed predict 
oS even when controlled for pathologic stage. Importantly, in 
patients who are not treated with neoadjuvant chemotherapy 
(Table 2), the percentage of viable tumor cells is not predic-
tive of oS. The prognostic effect of the percentage of viable 
tumor cells is significant when looked at in a continuous (p 
< 0.003) or categorical (>10% versus 10% viable tumor, p 
< 0.001) fashion and when controlled for pathologic stage 
(Table 3). Several other authors have observed a relationship 
FIGURE 3. Kaplan-Meier estimates of overall survival (A, C) and disease-free survival (B, D) based on pathologic stages (A, B) 
and percentage of viable tumor cells (C, D). A, The overall survival was significantly longer in patients with stages 0, IA, and IB 
than in patients with pathologic stage II, III, or IV. B, The disease-free survival was significantly longer in patients with stages 
0, IA, and IB than in patients with pathologic stage II, III, or IV. C, The overall survival was significantly longer in patients with 
10% viable tumor cells than in patients with >10% viable tumor cells. D, The disease-free survival was significantly longer in 
patients with 10% viable tumor cells than in patients with >10% viable tumor cells.
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with histopathologic response and survival in patients with 
NSCLC, but these studies have been limited by small num-
bers, variable types of induction therapy (chemotherapy and 
chemoradiation), and have not controlled for pathologic stage 
or included a control group of patients with NSCLC treated 
with surgery alone (Table 4).12–15 These studies evaluated 
only one slide for each tumor. Nevertheless, we evaluated 
multiple slides for each tumor on a large number of patients 
with NSCLC who only received neoadjuvant chemotherapy. 
Assessment of histopathologic response in the tumor was 
performed in a continuous (i.e., percent viable tumor) and 
categorical fashion (10%, 20%, 30%, 40%, or 50%, data not 
shown) with a modification of the regression grading sys-
tem introduced by Junker et al.,15 nonresponder = morpho-
logic evidence of therapy-induced changes but >10% viable 
tumor cells and responder = extensive response with 10% 
viable tumor cells. our study clearly demonstrates that the 
percentage of viable tumor cells is a significant predictor of 
oS and DFS in patients with neoadjuvant-treated NSCLC but 
not in those patients who undergo surgery alone. Although 
necrosis was present in patients with resected NSCLC who 
did not receive neoadjuvant therapy (Table 2), it was not pre-
dictive of oS or DFS. Although not statistically significant, 
there is a suggestion in the surgery-only patients (Table 2) 





HR (95% CI) p HR (95% CI) p
Univariate Cox  
 model
 Age (continuous) 192 1.01 (0.98–1.03) 0.59 1.00 (0.98–1.03) 0.8
 Gender 0.45 0.11
  Female  
  (reference)
81 1.00 1.00
  Male 111 0.85 (0.56–1.3) 0.71 (0.49–1.04)
 Histology 0.26 0.29
  Adenocarcinoma 
  (reference)
89 1.00 1.00
  Squamous cell  
  carcinoma
58 0.64 (0.38–1.09) 0.71 (0.45–1.14)
  other 45 0.89 (0.54–1.47) 0.76 (0.47–1.22)
 Pathologic stage <0.001 <0.001
  0/IA/IB  
  (reference)
78 1.00 1.00
  IIA/IIB 49 2.24 (1.22–4.11) 2.66 (1.55–4.58)
  IIA/IIB 57 4.23 (2.48–7.22) 4.54 (2.76–7.47)
  IV 8 7.69 (3.07–19.33) 6.73 (2.73–16.61)
 Viable tumor cells  
  (continuous)
192 1.02 (1.01–1.03) <0.001 1.01 (1.01–1.02) <0.001
Multivariate Cox  
 model
 Pathologic stage <0.001 <0.001
  0/IA/IB  
  (reference)
78 1.00 1.00
  IIA/IIB 49 1.85 (1.00–3.43) 2.36 (1.36–4.09)
  IIA/IIB 57 3.16 (1.80–5.52) 3.72 (2.19–6.31)
  IV 8 7.25 (2.88–18.29) 6.60 (2.66–16.33)
 Viable tumor cells  
 (continuous)
192 1.01 (1.00–1.02) 0.005 1.01 (1.00–1.02) 0.01
oS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; AJCC7, American Joint Committee on Cancer 7.
TABLE 4. Summary of Previous Histology Analysis on Patients with NSCLC Treated with Neoadjuvant therapy
Authors No. of Patients Stages Treatment Histologic Criteria Prognostic Data
Junker et al.12 40 IIIA and IIIB Combined chemotherapy and radiotherapy % Viable tumor 
(10% vs. >10%)
p = 0.02
Liu-Jarin et al.14 30 IIB, IIIA, IIIB, and IV Combined chemotherapy and radiotherapy % Viable tumor None
Yamane et al.15 53 I–IV 40 chemotherapy, 11 chemoradiotherapy, 
and 1 radiotherapy
Area of residual tumor 
(400 vs. >400 mm2)
p = 0.01
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that increased tumor necrosis is associated with reduced oS 
perhaps because larger tumors outgrow their native blood 
supply and are associated with a worse prognosis and less 
viable tumor.
Numerous histopathologic criteria were reviewed, and 
the only significant factors when controlled for pathologic 
stage were the percentage of viable tumor and stromal tis-
sue noted on the resected specimens. The percentage of 
necrosis did not correlate with oS or DFS (data not shown). 
This may have been due to the fact that a certain amount 
of necrosis is present in all tumors even those which are 
not treated with neoadjuvant chemotherapy. Several other 
histopathologic features such as cholesterin clefts, foreign 
body reactive giant cells, stromal hyalinosis, granulation 
tissue, and peripheral scar formation were associated with 
receiving neoadjuvant chemotherapy. Nevertheless, these 
histologic features had no significant correlation with clini-
cal response and prognosis. Additionally, several other his-
tologic features, such as coagulation necrosis, foam cell 
infiltration, and inflammatory cell infiltration, were pres-
ent in the resected specimens from both those patients who 
received neoadjuvant chemotherapy and those who under-
went surgical resection alone. Similar to the histologic fea-
tures related to neoadjuvant chemotherapy, there was no 
significant correlation of these unrelated histopathologic 
features to response and prognosis.
A potential limitation in our study is that variations 
of histologic features can occur in any grading system. In 
an attempt to decrease interobserver variability, all surgi-
cal specimens were histologically evaluated by two patholo-
gists. It is important to note that histopathologic criteria 
depend on complete sampling of the resected specimen, 
especially when no gross residual tumor is appreciable. 
As incomplete evaluation of the treated tumor site in cases 
with only rare microscopic foci of viable tumor could result 
in misclassification, examination of multiple tissue slices 
obtained from the tumor site is important for accurate and 
reproducible classification of histopathologic features. The 
variation between slides was as much as 5 to 10% in the 
same specimen. Because of this variability, we believe that 
it is important to assess numerous slides and take the mean 
of all the slides characterized (minimum of 1 slide per cm 
of resected tumor).
Chemotherapy resistance may be a significant contributor 
to treatment failure in some patients with NSCLC who receive 
neoadjuvant chemotherapy. A personalized approach to treat-
ment selection could potentially improve survival in patients 
with NSCLC who receive neoadjuvant therapy. In this regard, 
chemotherapeutic agents selected on the basis of molecular 
determinants of the tumor may augment response rates and 
survival. Clinical studies suggest that epidermal growth fac-
tor receptor mutations (particularly exon 19 deletions) have 
increased sensitivity to some chemotherapeutic agents.16–17 It 
has also been reported that high expression levels of excision 
repair crosscomplementation group 1 protein and ribonucle-
otide reductase predict resistance to platinum or gemcitabine 
chemotherapy.18,19 The histopathologic response reported in 
this article may form a surrogate end point for survival in 
phase II clinical trials. Such a surrogate end point would help 
accelerate biomarker-driven questions of response in trans-
lational clinical trials. The ability to separate biomarkers of 
response from biomarkers of prognosis may also be helped by 
assessment of pathologic response. The surrogate end point of 
pathologic response may ultimately be a better and faster cor-
relate for chemotherapy response than oS or DFS.
In summary, our results indicate that the percent-
age of viable tumor cells in the resected specimen corre-
lates with oS and DFS in patients with NSCLC treated 
with neoadjuvant chemotherapy even when controlled for 
pathologic stage. The routine histologic assessment of the 
resected specimen could potentially have a role in the sub-
sequent therapeutic management of patients who undergo 
surgery after neoadjuvant therapy. The percentage of via-
ble tumor cells in the resected specimen may also serve as 
a surrogate end point for survival and may provide a more 
accurate and rapid comparison between different neoadju-
vant treatment regimens, shortening the period needed to 
evaluate novel chemotherapeutic and biologic therapies in 
clinical trials.
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